A Phase 3 interventional study of Recombinant human luteinizing hormone (r-hLH) and Recombinant human follicle-stimulating hormone (r-hFSH) in Hypogonadism, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a prospective, open, non-comparative study to evaluate the safety and efficacy of recombinant human luteinizing hormone (rhLH, Luveris) administered subcutaneously (s.c.) in follicular development during ovulation induction in 31 Chinese female subjects with hypogonadotropic hypogonadism.
The objective of this prospective, open, non-comparative study was to assess the safety and efficacy of rhLH (Luveris) administered subcutaneously in follicular development during ovulation induction in Chinese female subjects with hypogonadotropic hypogonadism. The study was organized on an outpatient basis involving a single cycle of treatment. Prior to entry into the study, the diagnosis of hypogonadotropic hypogonadism was confirmed by history, by the presence or absence of specific clinical features and by measuring serum gonadotropin levels. Once a subject has signed the informed consent form and after satisfying all eligibility criteria, the subject received a combination of daily injection of recombinant human follicle-stimulating hormone (rhFSH) 150 international units (IU) plus rhLH 75 IU. After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU human chorionic gonadotropin (hCG). Luteal phase function was assessed by serum progesterone level determination.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
This study's enrollment of 31 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Browse Hypogonadism studies →Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One r-hLH (75 International Units \[IU\]) injection s.c. once daily.
Also known as: Luveris (r-hLH)
One r-hFSH (150 IU) injection s.c. once daily.
Also known as: Gonal-F (r-hFSH)
After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
Number of Participants Who Met Both Index 1 and Index 2
The three indices were defined as; Index 1: diameter of at least one follicle is greater than 17 mm; Index 2: serum oestradiol (E2) level in blood serum above 109 picogram/ milliliter (pg/mL) on human chorionic gonadotropin (hCG) injection day; Index 3: participant refuses to take hCG injection for the concern of ovarian hyperstimulation syndrome (OHSS) or participant is pregnant. A subset of these participants met Index 3.
Time frame: Day 14
Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter
Time frame: Day 14
Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection
Time frame: Day 14
Number of Participants Who Refused to Take hCG Injection
Participant refused to take hCG injection for the concern of OHSS or the participant was pregnant.
Time frame: Day 14
Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle
Time frame: Day 14
Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle
Time frame: Day 14
Average Change of E2 Level in Participants Per Day up to Day 14
The average change was calculated by assessing the E2 levels on 4 timepoints until day 14 (day 1, day 5, day 10, day 14 \[hCG administration day\]).
Time frame: up to Day 14
Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
Time frame: Day 14
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
Time frame: Day 14
| Milestone | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Started | 31 |
| Completed | 31 |
| Not completed | 0 |
The three indices were defined as; Index 1: diameter of at least one follicle is greater than 17 mm; Index 2: serum oestradiol (E2) level in blood serum above 109 picogram/ milliliter (pg/mL) on human chorionic gonadotropin (hCG) injection day; Index 3: participant refuses to take hCG injection for the concern of ovarian hyperstimulation syndrome (OHSS) or participant is pregnant. A subset of these participants met Index 3.
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Number of Participants Who Met Both Index 1 and Index 2 | 23 |
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter | 23 |
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection | 23 |
Participant refused to take hCG injection for the concern of OHSS or the participant was pregnant.
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Refused due to concern of OHSS | 0 |
| Refused due to pregnancy | 10 |
| follicles | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle | 3.57 ± 4.07 |
| follicles | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle | 2.13 ± 2.00 |
The average change was calculated by assessing the E2 levels on 4 timepoints until day 14 (day 1, day 5, day 10, day 14 \[hCG administration day\]).
| pg/mL per day | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Average Change of E2 Level in Participants Per Day up to Day 14 | 71.03 ± 64.53 |
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Biochemical Pregnancies | 1 |
| Clinical Pregnancies | 9 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
| participants | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Adverse Events | 0 |
| Serious Adverse Events | 0 |
Collected over Day 14. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Human Luteinizing Hormone (Luveris) | — | 0/31 (0%) | 0/31 (0%) |
| Age, Continuous(years) | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Mean | 30.1 ± 4.09 |
| Sex: Female, Male(Participants) | Recombinant Human Luteinizing Hormone (Luveris) |
|---|---|
| Female | 30 |
| Male | 0 |
The record gives a start of Feb 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutropin alfa
Merck KGaA, Darmstadt, Germany →